Home
Arvinas

Arvinas Market Share Analysis for August 2026

Learn more about Arvinas' pipeline and R&D focused on advancing neurology and oncology programs.

Health > Biotechnology and Pharmaceuticals

Domainarvinas.com

Year Founded2013

Employees201 - 500

Annual Revenue$200M - $500M

Arvinas

Arvinas (including company regionals)

arvinas.com

See more website traffic and engagement information

Arvinas Revenue up to August 2026 is 200M - 500M

revenue generated by Arvinas top domains

Arvinas top domains revenue over 3 years

Revenue for Arvinas top domains

arvinas.com200M - 500M

See more with Sales Intelligence

Total visits to Arvinas's top domains

Understand Arvinas market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

arvinas.com12.1K

See more with Sales Intelligence

Avg. visit duration in Arvinas's top domains

Analyze Arvinas engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

arvinas.com00:00:25

See more with Sales Intelligence

Avg. pageviews on Arvinas's top domains

See how Arvinas keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

arvinas.com1.71

See more with Sales Intelligence

Arvinas top competitors by domain

Top similar sites in August 2026, ranked by their affinity

nanobiotix.comCompany NameNanobiotixEmployees51 - 200HQFrance, ParisAnnual revenue$25M - $50MTotal visits5.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Arvinas

These are the website technologies, by industry, used by Arvinas top domains

Payment & Currencies (8)

Cart Functionality

Widget (8)

Twemoji

Conversion & Analytics (5)

Google Analytics

Content Management System (4)

WordPress

More Technologies

9

See all

News & Signals from Arvinas

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsArvinas is developing protein degradation therapies on Sep 3rd '26.Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

NewsArvinas, Inc. is developing PROTAC degraders for mutant huntingtin, tau and alpha-synuclein.* U.S.-based Arvinas is working on PROTAC degraders for mutant huntingtin, tau and alpha-synuclein - three proteins linked to Huntington's, Alzheimer's and Parkinson's disease.

NewsArvinas, Inc. attended event Jefferies Global Healthcare Conference on Jun 3rd '26.NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.